Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.65 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.52 |
| ▸ | CYP19A1 known ✓ | P11511 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.94 |
| ▸ | APP | P05067 | 2/20 | 0.70 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | CA9 | Q16790 | 2/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3947579 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1CYP3A4MAPK1APP | |
| Hydrochloric Acid SCHEMBL1827219 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1CYP3A4MAPK1APP | |
| Hydrochloric Acid SCHEMBL27958988 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1CYP3A4MAPK1APP | |
| Hydrochloric Acid SCHEMBL4376059 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1CYP3A4MAPK1APP | |
| SCHEMBL5097 | 0.97 | — | — | |
| SCHEMBL8526630 | 0.97 | TDP1 (1.00) | ALDH1A1TDP1CYP3A4MAPK1APP | |
| Ethane SCHEMBL11031442 | 0.94 | TDP1 (0.94) | ALDH1A1TDP1CYP3A4MAPK1APP | |
| SCHEMBL5601373 | 0.94 | TDP1 (0.94) | ALDH1A1TDP1CYP3A4MAPK1APP | |
| SCHEMBL21840887 | 0.94 | TDP1 (0.94) | ALDH1A1TDP1CYP3A4MAPK1APP | |
| Methane SCHEMBL22289589 | 0.94 | TDP1 (0.94) | ALDH1A1TDP1CYP3A4MAPK1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 811 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118910629-A | Electrochemical synthesis method of quinazolinone derivative | 齐齐哈尔医学院 | 2024-11-08 | — | — | CN | claimed |
| US-20230159476-A1 | PROCESS FOR THE SYNTHESIS OF COMPOUNDS WHICH ABSORB ULTRAVIOLET RADIATION IN FLOW CONDITIONS AND FORMULATIONS COMPRISING SAME | ELIKIMIA INC (CA) | 2023-05-25 | — | — | US | claimed |
| CN-115768755-A | Method for synthesizing compounds absorbing ultraviolet radiation under flow conditions and formulations containing the same | 爱尔克米亚公司 | 2023-03-07 | — | — | CN | claimed |
| CN-115677648-A | Synthesis method of lactide with high optical purity | 扬州大学 | 2023-02-03 | — | — | CN | claimed |
| CN-217747075-U | Anethole hydrochloride making devices | 辽宁兰得新材料科技发展有限公司 | 2022-11-08 | — | — | CN | claimed |
| CN-217735854-U | Vacuum pump is used in production of methoxamine hydrochloride | 常州瑞明药业有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-114685290-A | Preparation method of methoxyphenamine hydrochloride | 杭州国瑞生物科技有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-209848351-U | A rotary evaporator for producing methoxamine hydrochloride | 常州瑞明药业有限公司 | 2019-12-27 | — | — | CN | claimed |
| CN-110144640-A | A kind of processing method of degradable fishing net | 巢湖市翔宇渔具有限公司 | 2019-08-20 | — | — | CN | claimed |
| CN-110004162-A | A kind of carbonyl reductase, gene and its application on methoxyphenamine hydrochloride key intermediate | 长兴制药股份有限公司 | 2019-07-12 | — | — | CN | claimed |
| CN-1479628-A | Use of CYP206 inhibitors in combination therapies | �Ʒ� | 2004-03-03 | — | — | CN | claimed |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS PHARMACEUTICALS, INC. | 2003-12-25 | — | — | US | claimed |
| CN-1118701-C | Method for detecting composition of carena, methoxyphenamine hydrochloride, narcotine, etc at same time | UNIV FUDAN (CN) | 2003-08-20 | — | — | CN | claimed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| CN-1273361-A | Method for detecting composition of carena, methoxyphenamine hydrochloride, narcotine, etc at same time | UNIV FUDAN (CN) | 2000-11-15 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159476-A1 | PROCESS FOR THE SYNTHESIS OF COMPOUNDS WHICH ABSORB ULTRAVIOLET RADIATION IN FLOW CONDITIONS AND FORMULATIONS COMPRISING SAME | ERCC4, XPA, ERCC1 | CA2 4519/4885ACHE 3842/4885CYP19A1 630/4885 |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | CA2 3673/4885ACHE 4112/4885CYP19A1 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.